Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 462
- Registration Number
- NCT03457012
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Cambridge, Ontario, Canada
Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1 Diabetes
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 320
- Registration Number
- NCT03450863
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Schweinfurt, Germany
Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
Phase 4
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT03449342
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, New Delhi, India
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT03444467
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT03435627
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)
Completed
- Conditions
- Haemophilia A, Haemophilia B, Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 317
- Registration Number
- NCT03430154
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin degludec /insulin aspart
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 768
- Registration Number
- NCT03416855
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Ulsan, Korea, Republic of
A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT03407599
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 225
- Registration Number
- NCT03377699
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 516
- Registration Number
- NCT03374774
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Thriruvananthapuram, India
© Copyright 2025. All Rights Reserved by MedPath